When you have tried more than one antidepressant without the relief you hoped for, it is natural to feel cautious about the next option. You want to know that a treatment has been carefully studied and that it is being used the way it was intended. Those are fair concerns, and they deserve clear answers.
The FDA approval of SPRAVATO® in Squirrel Hill gives adults with treatment-resistant depression access to an esketamine nasal spray that has gone through a rigorous federal review. At The Nexus Group, we provide SPRAVATO® treatment in a certified office setting, and it is covered by most major insurance plans. Understanding what FDA approval includes can help you decide whether this path makes sense for you.
The FDA first approved SPRAVATO® in March 2019 for adults with treatment-resistant depression, used alongside an oral antidepressant. Later decisions in 2020 and 2025 expanded how it can be prescribed. Treatment-resistant depression generally means your symptoms have not improved enough after trying at least two oral antidepressants.
In August 2020, the FDA added a second use: easing depressive symptoms in adults with major depressive disorder (MDD) who have acute suicidal thoughts or behavior, in combination with an oral antidepressant.
In January 2025, the agency approved SPRAVATO® as a standalone option for treatment-resistant depression. For adults in Squirrel Hill with this condition, approved esketamine treatment may now be used with or without a daily oral antidepressant.
Because of possible sedation, dissociation, and misuse, the FDA made SPRAVATO® available only through a restricted program known as Risk Evaluation and Mitigation Strategy (REMS). Under this program, you cannot take the nasal spray home, and every dose happens in a certified healthcare setting. This structure keeps a trained team beside you during the period when side effects are most likely to appear.
At our office, approved SPRAVATO® treatment in Squirrel Hill follows these requirements closely. You self-administer each dose under our supervision, and then you remain with us for at least two hours while we check your blood pressure and watch for side effects. You will also need someone to drive you home, since driving is not advised until the next day after a restful night of sleep.
Approval means the FDA reviewed clinical trial data and determined that the benefits of SPRAVATO® outweigh its risks for the specific conditions on its label. It also sets clear boundaries, since the treatment is approved for adults only and is not intended for every type of depression. Our psychiatrists respect those limits, so any recommendation we make stays within the uses the FDA has reviewed.
For many people in Squirrel Hill seeking esketamine nasal spray, FDA approval also matters when it comes to cost. Because SPRAVATO® has an established, approved use, most major insurance plans cover treatment for patients who meet their criteria. Our team can review your benefits and help with any prior authorization your plan requires.
Living with depression that has not responded to standard treatment can be exhausting, but you still have options backed by careful review. SPRAVATO® treatment offers a monitored, structured approach that our team shapes around your symptoms and goals.
If you have questions about the FDA approval of SPRAVATO® in Squirrel Hill or want to know whether you qualify, our psychiatrists are here to help. Contact The Nexus Group to schedule an appointment and take a confident next step in your care.
